MedTrace Logo

Molecular Diagnosis on Circulating Tumor DNA of Non-Small Cell Lung Cancer

NCT02169349 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2016-09-12

No results posted yet for this study

Summary

The purpose of this study is to develop an ultra sensitive assay of mutation detection on circulating tumor DNA (ctDNA) for treatment, diagnosis and monitoring disease progression of Non-Small Cell Lung Cancer (NSCLC).

Conditions

  • Stage IIIb and IV Non Small Cell Lung Cancer

Interventions

OTHER

laboratory biomarker analysis

OTHER

Next Generation Sequencing

GENETIC

DNA Analysis

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Rennes University Hospital

    lead OTHER

Principal Investigators

  • Jean Mosser, PUPH · Rennes University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2016-06-30
Completion
2016-09-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02169349 on ClinicalTrials.gov